Search PubMed⌕ Search

Biomedical subjects

W A Orenstein

Publications and source records attributed to W A Orenstein.

At least 19 recordsLinked to original sources

Vaccination policies and programs: the federal government's role in making the system work.

Government agencies play a key role, from preclinical development to postlicensure monitoring, in making vaccinations one of the leading public health interventions. Important steps in this process include development and testing of vaccine antigens, evaluation of clinical and manufacturing data leading to licensure, formulation of recommendations, vaccine purchase, defining strategies to improve coverage, compensation of those injured by vaccine adverse reactions, and monitoring vaccine impact and safety. Using examples of newly recommended vaccines, this article describes the infrastructure that underlies a safe and effective program and highlights some of the opportunities and threats likely to impact the system in coming years.

Adverse Drug Reaction Reporting Systems↗

Measles eradication: is it in our future?

Measles eradication would avert the current annual 1 million deaths and save the $1.5 billion in treatment and prevention costs due to measles in perpetuity. The authors evaluate the biological feasibility of eradicating measles according to 4 criteria: (1) the role of humans in maintaining transmission, (2) the availability of accurate diagnostic tests, (3) the existence of effective vaccines, and (4) the need to demonstrate elimination of measles from a large geographic area. Recent successes in interrupting measles transmission in the United States, most other countries in the Western Hemisphere, and selected countries in other regions provide evidence for the feasibility of global eradication. Potential impediments to eradication include (1) lack of political will in some industrialized countries, (2) transmission among adults, (3) increasing urbanization and population density, (4) the HIV epidemic, (5) waning immunity and the possibility of transmission from subclinical cases, and (6) risk of unsafe injections. Despite these challenges, a compelling case can be made in favor of measles eradication, and the authors believe that it is in our future. The question is when.

Adult↗

The immunization system in the United States - the role of school immunization laws.

School immunization laws have had a remarkable impact on vaccine-preventable diseases in the United States, particularly in school-aged populations. Enforcement of laws through the exclusion of unvaccinated children from school is a critical factor in assuring success. All laws have exemptions for medical contraindications, 47 states have exemptions for persons with strong religious beliefs against vaccination and 15 states have exemptions for persons philosophically opposed to vaccination. Fewer than 1% of students have any type of exemption in most states. School laws harness the resources of other programs such as education to the immunization effort. They establish a safety net to assure high levels of coverage each and every year. But they cannot replace efforts to assure age appropriate immunization in the first two years of life.

Adolescent↗

Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination.

Transmission of pertussis among adults is being increasingly recognized. About 1 or 2 in 1,000 adolescents and adults develop pertussis each year, > or = 12% of persons with acute cough illnesses of at least 1-2 weeks' duration have evidence of pertussis infection, and adults have been the source of pertussis for younger children. The advent of acellular pertussis vaccines, if safe and effective in adults, offers the opportunity to prevent transmission of pertussis in older populations. Several issues should be clarified before routine immunization is recommended, including the health burden of pertussis in adults and adolescents to be prevented by vaccination and how much morbidity resulting from pertussis in infants and children would be indirectly prevented. Preliminary studies suggest that pertussis vaccines are safe and immunogenic in adults. Potential recommendations for future vaccination might include all adolescents and adults at 10-year intervals along with the adult tetanus-diphtheria toxoids booster. Cost-benefit or cost-effectiveness analyses would be useful in developing vaccination policies for adults.

Adolescent↗

Vaccines. Overview.

Explore the source record for details and available documents.

Communicable Disease Control↗

Addressing the challenges to immunization practice with an economic algorithm for vaccine selection.

The biotechnology revolution is producing a growing bounty of new vaccines which pose difficult choices in selecting among many products. Some major public and private purchasers of vaccine may offer individual physicians and clinics their choice in assembling vaccine inventories. Others might purchase only a limited stock of products that would satisfactorily immunize a typical child. In either case, current vaccine selection decisions are based principally on purchase price alone without systematic consideration of other factors of fiscal consequence. As a potential tool for decision making, we developed an economic algorithm for vaccine selection that would minimize the overall costs of disease control through immunization by considering: (1) purchase price, (2) number of doses needed, (3) preparation time, (4) route of administration, (5) cold storage needs, (6) shelf life, (7) earliest age of full immunity, (8) adverse events frequency, and (9) efficacy of protection. To demonstrate the algorithm, variables (1) to (4) above were incorporated into a pilot binary-integer linear programming model that satisfied the recommended immunization schedule for diphtheria, tetanus, pertussis, Haemophilus influenzae b, and hepatitis B, using eleven vaccines (DTaP, DTaP-Hib, Hib, HepB and Hib-HepB) from four manufacturers. Five (or six) opportunities to vaccinate were modeled at (1), 2, 4, 6, 12-18, and 60 months of life, assuming US$40 per clinic visit, $15 per injection, and $0.50 per minute of nurse preparation time. Vaccine costs were varied using actual March and September 1997 US Federal vaccine prices, as well as estimates for unpriced new vaccines. Over 16,000 distinct vaccine stocking lists by vaccine type and brand were possible. Including a 1-month visit, the lowest-cost 'solution' of the algorithm was $529.41 per child in the March cost-assumption case, and $490.32 in the September one (both included four doses of DTaP-Hib, three HepB, and one DTaP). Without a 1-month visit, the lowest-cost solution in the March case cost $486.67 (four DTaP, two Hib-HepB, one DTaP-Hib, and one HepB), while the September case cost $450.32 (four DTaP-Hib, three HepB, and one DTaP). Ensuring at least one product was selected from each of the four manufacturers increased costs about $13.00, and the needed injections rose from eight to nine. The most economical selection of vaccines to use cannot be intuitively predicted, as permutations are large and solutions are sensitive to minor changes in costs and constraints. A transparent, objective selection method that weighs the economic value of distinguishing features among competing vaccines might offer the 'best value' to vaccine purchasers, while also creating strong market incentives for continuing innovation and competition in the vaccine industry.

Adolescent↗

Rotavirus vaccines--from licensure to disease reduction.

Rotavirus infection produces a serious health burden in the United States, causing an estimated > 100,000 hospitalizations and > 100 deaths annually. This health burden is comparable to that for measles, pertussis, mumps, and varicella before vaccines for these diseases were routinely given to children. Rotavirus vaccines have the potential to significantly reduce a serious public health problem in the United States. However, while development and licensure of vaccines is a major breakthrough, it represents only the first step in disease prevention. Vaccines must be recommended by major immunization advisory committees, financed in both the public and private sectors, and successfully integrated into the existing vaccination schedule. Vaccines must reach all targeted children, and monitoring systems must be established or adapted to better determine vaccine safety and disease impact. Reevaluation of disease prevention strategies must be ongoing and fueled by new information on safety and disease reduction.

Child, Preschool↗

The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak.

A common source of bias in evaluating vaccine efficacy following a disease outbreak is the presence of persons who had the disease prior to the outbreak. This paper examines the effects of including and excluding pre-outbreak disease cases from the calculation of vaccine efficacy based on the cumulative incidence at the end of an outbreak. Using a five-stage model, the effects of the following factors on the bias of vaccine efficacy estimates are examined: the true protective efficacy of the vaccine, the prevaccination infection rate, differences in vaccine uptake among the previously diseased and nondiseased, differences in pre-outbreak exposure to infection between vaccinees and nonvaccinees, and differences in exposure during the outbreak between vaccinees and nonvaccinees. Numerical calculations of the bias are performed for a hypothetical outbreak of measles in a developing country. Exclusion of pre-outbreak disease cases requires accurate data on disease rates prior to the outbreak, and such data are often unreliable or nonexistent. Inclusion of pre-outbreak cases contributes to the bias of the estimated vaccine efficacy, especially when there is a high prevaccination infection rate and vaccine uptake among the previously diseased is considerably lower than that among the nondiseased. In most practical cases, however, this bias is not very large.

Disease Outbreaks↗